NHS and Private Network Leverage Source LDPath’s established footprint with over 85 NHS Trusts and a wide private healthcare network to cross-sell digital pathology, AI-enabled workflows, and molecular diagnostics capabilities to existing hospital and clinic partners.

Digital Pathology Focus Offer integrated digital pathology and AI solutions via HALO AP platform (via Indica Labs) to accelerate diagnostic reporting, increase throughput, and provide scalable outsourcing options for NHS pathology departments and private labs.

Genomics Breadth Promote Source Genomics’ multi-omics services including WGS, WES, RNA-seq, spatial transcriptomics, proteomics, and advanced bioinformatics to biopharma and academia pursuing comprehensive biomarker discovery and translational research.

Strategic Acquisitions Capitalize on recent acquisitions and partnerships (Cambridge Clinical Laboratories, Stilla Technologies collaboration) to position Source BioScience as a one-stop provider for diagnostic biomarker validation, dPCR capabilities, and expanded sequencing capacity.

Growth Opportunities Target expansion into high-value testing areas such as early cancer diagnostics, biomarker-driven trials, and NHS outsourcing programs by aligning services with clinically actionable turnaround times and LIMS integration through Source HIVE.